Medtronic plc (MDT) company profile
Close on Nov 17, 2026Market cap $130.88BP/E 25.1Yield 2.78%
About Medtronic
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Medtronic plc is a global healthcare technology enterprise that engineers, manufactures, and markets device-based therapies and medical solutions. The company operates primarily through three core portfolios: Cardiovascular, Neuroscience, and Medical Surgical. Its offerings encompass cardiac pacemakers, defibrillators, ablation catheters, heart valves, and stent grafts, as well as cranial and spinal implants, surgical navigation, robotic guidance systems, neurostimulators, and drug delivery devices. Additionally, it provides advanced surgical tools, electrosurgical instruments, hernia meshes, and patient monitoring and airway management equipment. Medtronic supplies its products to healthcare systems, hospitals, ambulatory surgery centers, physician clinics, and specialized medical professionals across numerous clinical disciplines.
The company conducts commercial activities globally, serving customers in more than 150 countries. Its international manufacturing footprint spans production facilities worldwide, supported by a global workforce exceeding 95,000 full-time employees, with 43% located in the United States and Puerto Rico. Medtronic maintains its corporate headquarters in Galway, Ireland.
Summary of the business section of Medtronic's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Medtronic plc
- Founded
- 1949
- Headquarters
- Galway, Ireland
- Address
- Building Two Parkmore Business Park West H91 4K49
- Phone
- 01135314381700
- Website
- www.medtronic.com
- Employees
- 95,000, Apr 24, 2026
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Fiscal year ends
- April 24
- Auditor
- PricewaterhouseCoopers LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- MDT
- Exchange
- NYSE
- IPO date
- May 2, 1973
- Shares outstanding
- 1.28B, Aug 28, 2026
- Public float
- $120.10B, Oct 24, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Sep 27, 1999; 2-for-1, Sep 15, 1997; 2-for-1, Sep 29, 1995; 2-for-1, Sep 30, 1994; 2-for-1, Aug 30, 1991; 2-for-1, Aug 31, 1989; 2-for-1, Aug 1, 1980
- SEC CIK
- 1613103
- CUSIP
- G5960L103
- FIGI
- BBG000BNWG87
- Share class FIGI
- BBG001S5T2S9
- LEI
- 549300GX3ZBSQWUXY261
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Geoffrey Martha | Chairman and CEO, Director | 277,866 |
| Michael Marinaro | President | 113,353 |
| Harry Skip Kiil | EVP & President Cardiovascular | 42,186 |
| Denise L. Blomquist | Chief Accounting Officer | 16,398 |
| Kweli Thompson | EVP & President, Neuroscience | 35,390 |
| Michelle Quinn | EVP, GC and Secretary | 26,721 |
| Matthew R. Walter | SVP, Chief HR Officer | 39,928 |
| Thierry Pieton | EVP & Chief Financial Officer | 49,645 |
| Brett A. Wall | EVP & Pres Neuroscience | 82,183 |
| Gregory L. Smith | EVP Global Ops & Supply Chain | 51,830 |
| Gary Louis Corona | Interim CFO | 44,255 |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | 54,692 |
| Sean Salmon | EVP & President Cardiovascular | 64,722 |
| Jennifer M. Kirk | Chief Accounting Officer | 28,011 |
| Kevin E. Lofton | Director | 9,977 |
| Joon Sup Lee | Director | 1,803 |
| Craig Arnold | Director | 42,185 |
| William R. Jellison | Director | 6,444 |
| Scott C. Donnelly | Director | 23,924 |
| Randall J. Hogan | Director | 86,082 |
| Kendall J. Powell | Director | 54,380 |
| Lidia Fonseca | Director | 7,644 |
| Elizabeth G. Nabel | Director | 19,584 |
| John P. Groetelaars | Director | 1,444 |
| Gregory P. Lewis | Director | 5,754 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $22.94M | $22.45M | $7.27M | $74 | $97 |
| FY2025 Geoff Martha | $21.24M | $26.09M | $5.65M | $98 | $149 |
| FY2025 Martha | $21.24M | $26.09M | $5.65M | $98 | $149 |
| FY2024 Geoff Martha | $20.08M | $11.12M | $7.59M | $90 | $135 |
| FY2024 Martha | $20.08M | $11.12M | $7.59M | $90 | $135 |
| FY2023 | $15.39M | $3.32M | $5.39M | $99 | $131 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Geoff Martha Chairman and Chief Executive Officer | $1.40M | – | $13.67M | $5.18M | $2.31M | $386.26K | $22.94M | +8% |
| Thierry Piéton EVP, Chief Financial Officer | $849.65K | $2.00M | $3.17M | $1.20M | $963.05K | $404.08K | $8.59M | +65% |
| Brett Wall Former EVP & President, Neuroscience Portfolio | $799.52K | – | $3.57M | $1.35M | $824.00K | $381.05K | $6.92M | -15% |
| Mike Marinaro EVP & President Medical Surgical Portfolio & Americas | $819.62K | – | $3.57M | $1.35M | $971.29K | $125.08K | $6.83M | – |
| Michelle Quinn EVP, General Counsel and Secretary | $600.00K | $1.10M | $3.48M | $750.08K | $617.42K | $170.07K | $6.72M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“Medtronic has over 95,000 full-time employees, of which 43% are based in the U.S.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?